Trump Administration
Refine Search
Pharmaceutical
US President Donald Trump issued an executive order on April 15 listing several potential policy changes aimed at lowering US drug prices.
Responding to the announcement, Morningstar’s healthcare equity research director Karen Andersen gave her views on why this matters. 18 April 2025
Pharmaceutical
US President Donald Trump has passed an executive order that answers the pharmaceutical industry’s calls for the scrapping of the Inflation Reduction Act’s (IRA) ‘pill penalty’. 16 April 2025
Pharmaceutical
New research from consultancy Vital Transformation has shown the effects of US policy the Inflation Reduction Act’s (IRA) drug pricing provisions on biopharmaceutical investment, research and development (R&D). 15 April 2025
Biotechnology
US sequencing firm PacBio is cutting jobs and reducing spending across its business as it braces for the financial impact of new global tariffs and growing uncertainty around federal research funding. 14 April 2025
Biotechnology
Shares in US biotech Novavax fell more than 20% before the weekend, following remarks from health and human services secretary Robert F Kennedy Jr, who questioned the scientific basis of the company’s COVID-19 vaccine in a televised interview. 14 April 2025
Pharmaceutical
Speculation about the US Administration’s views on the Pharmaceutical Benefits Scheme (PBS) has reconfirmed the sanctity of the PBS as the cornerstone of Australia’s healthcare system, the domestic pharma trade group stressed. 11 April 2025
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS) has announced action intended to preserve the core mission of the Medicaid program against a wider backdrop of wider cost-cutting under the regime of President Donald Trump. 11 April 2025
Biotechnology
Licensing agreements for Chinese drug candidates hit a record high in 2024, with large pharma in-licensing 28% of innovator drugs from Chinese biopharma companies. 9 April 2025
Biotechnology
A federal commission has urged the US government to invest $15 billion to protect the country’s leadership in biotechnology and prevent China from outpacing American innovation in the field. The warning comes amid rising concern over growing reliance on foreign manufacturing and increasing Chinese activity in licensing biotech assets. 9 April 2025
Pharmaceutical
Ireland’s government remains confident in its ability to retain the country’s strategic position in pharmaceutical manufacturing, despite rising tensions between the European Union and the United States over trade policy. 8 April 2025
Pharmaceutical
Thousands of workers dismissed from the US Department of Health and Human Services this week may soon be reinstated, after health secretary Robert F Kennedy Jr admitted that a significant share of the job cuts were made in error. 7 April 2025
Pharmaceutical
In the news last week, US Center for Biologics Evaluation and Research (CBER) Dr Peter Marks quit his post after reported pressure from a Human Health Services (HHS) official. On the research front, Merck & Co presented positive Phase III data on its Winrevair in pulmonary arterial hypertension (PAH) at the American College of Cardiology (ACC) meeting. Also, Swiss biotech AC Immune shared new Phase II data on its Parkinson’s disease candidate ACI-7104-056. Late last Wednesday, US President Donald Trump dropped a bombshell of tariffs of various amounts on countries around the world, although there was ambiguity as to how and when they would impact pharma and biotech products. 6 April 2025
Biotechnology
US biotech Novavax is still waiting on a decision from the Food and Drug Administration over full approval of its protein-based COVID-19 vaccine, despite the agency having set an April 1 target date to complete its review. 4 April 2025
Pharmaceutical
Pharmaceuticals will be exempt from the tariffs on imports to the USA that were announced by US President Donald Trump Wednesday, according to a White House fact sheet. 3 April 2025
Pharmaceutical
Freed from their former obligations to remain loyal to agency and state, a number of high-profile figures from the US Food and Drug Administration (FDA) have sounded the alarm about its direction of travel under Robert Francis Kennedy Jr (RFK Jr), the new Secretary of Health and Human Services. 2 April 2025
Pharmaceutical
The US government is reclaiming over $11 billion in unspent public health funds originally allocated during the COVID-19 emergency, a move that has drawn sharp criticism from lawmakers and public health advocates who warn it will weaken the country’s ability to respond to future health threats and disrupt essential care services. 31 March 2025
Pharmaceutical
There has been talk of the job cuts impacting US health agencies for weeks. 27 March 2025
Pharmaceutical
The US Senate has confirmed President Donald Trump’s nominees to lead two of the country’s top health agencies, approving surgeon Marty Makary as Commissioner of the Food and Drug Administration and economist and physician Jay Bhattacharya as director of the National Institutes of Health. 27 March 2025
Biotechnology
The US Biotechnology Innovation Organization (BIO) has released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. 27 March 2025
Pharmaceutical
The Trump administration plans to pull US funding from Gavi, the global vaccine alliance that helps deliver immunizations to children in lower-income countries, according to internal documents obtained by the New York Times. 26 March 2025
Pharmaceutical
The US National Institutes of Health (NIH) has awarded a grant of up to $4.6 million to Sydney University spinout Kinoxis Therapeutics, under an initiative aimed at combating the epidemic of opioid addiction in America. 30 September 2019
Pharmaceutical
A year after the US Government passed controversial “Right to Try” legislation, the first contract research organizations (CRO) are gearing up to provide people with access to experimental medicines. 18 September 2019
Pharmaceutical
More than $1.8 billion has been released by the US Department of Health and Human Services (HHS) to help combat the opioid crisis in the USA. 5 September 2019
Pharmaceutical
US President Donald Trump is reviving a stalled effort to compel drugmakers to list drug prices in direct to consumer (DTC) advertising, after a court struck down the initiative. 22 August 2019
Biotechnology
The recently-approved CAR-T therapies Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) have come with a price tag to match the level of scientific innovation. 8 August 2019
Pharmaceutical
The US Department of Health and Human Services (HHS) and the country’s Food and Drug Administration (FDA) have announced a plan to import certain prescription drugs in order to lower prices for patients. 31 July 2019
Pharmaceutical
Shares in major pharmaceutical companies fell on Thursday, after the US government said it would abandon a proposal to require health insurers to pass significant rebates on to Medicare patients. 12 July 2019
Pharmaceutical
Last month, the US Department of Health and Human Services (HHS) announced a new rule demanding that direct-to-consumer television advertisements for certain pharmaceuticals and biologics state the list price of the medicine being advertised. 17 June 2019
Pharmaceutical
Amid multiple Congressional investigations into drug pricing in the USA, and a febrile political atmosphere around the role of the state in insurance and pricing negotiations, the nonpartisan Congressional Budget Office (CBO) released a report into so-called “Medicare for all” on Thursday. 2 May 2019
Pharmaceutical
US Health Secretary Alex Azar has outlined progress combating the ongoing opioid crisis, with an update one year on from a pledge from the US President to reduce unnecessary opioid prescriptions, expand treatment, and boost access to naloxone. 25 April 2019
Pharmaceutical
Representatives from pharmacy benefit managers (PBMs) were the latest to be grilled by lawmakers in Washington DC on Tuesday. 10 April 2019
Pharmaceutical
Most commercial executives in the industry thought the discussions over Obamacare were finally at an end, after a monthslong war of attrition between the White House and Congress early in Mr Trump’s presidency. They may need to think again. 27 March 2019
Pharmaceutical
The US Food and Drug Administration has announced new final guidance on HIV prevention, following US President Donald Trump’s recently-announced effort to eliminate the HIV epidemic within America. 20 March 2019
Pharmaceutical
Reflecting its growing standing as an opinion leader on all things drug price-related, the Institute for Clinical and Economic Review (ICER)—in collaboration with the Office of Health Economics (OHE) —has published a white paper looking at alternative models for pharmaceutical rebates in the USA. 13 March 2019
Pharmaceutical
US President Donald Trump recently promised a cheering Miami crowd that America "will never be a socialist country." Let's hope!, writes Institute for Policy Innovation (IPI) resident scholar Dr Merrill Mathews. 9 March 2019
Generics
Research shows some 79% of the American public view the cost of prescription drugs as unreasonable, and lawmakers and regulators are increasingly convinced the industry charges too much for its products. 8 March 2019
Pharmaceutical
In Washington DC on Tuesday, the chief executives of half a dozen leading drugmakers defended the industry’s drug pricing rationale and shifted the blame for high prices onto the sector’s intermediaries. 27 February 2019
Pharmaceutical
Buyers of pharmaceutical stocks are watching closely as the heads of some of the world’s biggest drugmakers give evidence before Congress on their companies’ pricing practices. 26 February 2019
Pharmaceutical
Six chief executives of global pharma companies are due to face questions from senior US senators on Tuesday, as lawmakers from both legislative chambers progress inquiries into the industry’s pricing practices. 25 February 2019
Pharmaceutical
The US Health and Human Services Secretary Alex Azar and Inspector General Daniel Levinson have proposed a rule to lower prescription drug prices and out-of-pocket costs by encouraging manufacturers to pass discounts directly on to patients. 1 February 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze